CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback